Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.47 | N/A | +21.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.47 | N/A | +21.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the ongoing challenges in the market. They emphasized their commitment to long-term objectives while acknowledging short-term difficulties.
The company is navigating a challenging market environment.
We remain focused on our long-term goals despite current setbacks.
The earnings report indicates that Terns Pharmaceutical is still facing challenges, as evidenced by the negative stock reaction of 4.93%. Despite a positive surprise in EPS, the lack of revenue data and guidance may have contributed to investor uncertainty. The management's defensive tone suggests that the company is cautious about its near-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WARBY PARKER INC A
Nov 12, 2021